Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver

被引:23
|
作者
van Dijk, F. [1 ,2 ]
Teekamp, N. [1 ]
Beljaars, L. [2 ]
Post, E. [2 ]
Zuidema, J. [3 ]
Steendam, R. [3 ]
Kim, Y. O. [4 ]
Frijlink, H. W. [1 ]
Schuppand, D. [4 ,5 ]
Poelstra, K. [2 ]
Hinrichs, W. L. J. [1 ]
Olinga, P. [1 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands
[2] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands
[3] InnoCore Pharmaceut, Groningen, Netherlands
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immune Therapy, Inst Translat Immunol, Mainz, Germany
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
Controlled release; Biodegradable polymeric microspheres; PDGF beta-receptor targeted drug carrier; Protein delivery; in vitro in vivo correlation; Liver fibrosis; GROWTH-FACTOR RECEPTOR; DRUG-DELIVERY; ANTIFIBROTIC THERAPIES; POLYMERIC MICROSPHERES; MULTIBLOCK-COPOLYMER; INTERFERON-GAMMA; IN-VIVO; FIBROSIS; IMPLANTS; MICE;
D O I
10.1016/j.jconrel.2017.11.029
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Liver fibrogenesis is associated with excessive production of extracellular matrix by myofibroblasts that often leads to cirrhosis and consequently liver dysfunction and death. Novel protein-based antifibrotic drugs show high specificity and efficacy, but their use in the treatment of fibrosis causes a high burden for patients, since repetitive and long-term parenteral administration is required as most proteins and peptides are rapidly cleared from the circulation. Therefore, we developed biodegradable polymeric microspheres for the sustained release of proteinaceous drugs. We encapsulated the drug carrier pPB-HSA, which specifically binds to the PDGF beta R that is highly upregulated on activated myofibroblasts, into microspheres composed of hydrophilic multi-block copolymers composed of poly(L-lactide) and poly ethylene glycol/poly(is an element of-caprolactone), allowing diffusion-controlled release. Firstly, we estimated in mice with acute fibrogenesis induced by a single CCl4 injection the half-life of I-125-labeled pPB-HSA at 40 min and confirmed the preferential accumulation in fibrotic tissue. Subsequently, we determined in the Mdr2-/- mouse model of advanced biliary liver fibrosis how the subcutaneously injected microspheres released pPB-HSA into both plasma and fibrotic liver at 24 h after injection, which was maintained for six days. Although the microspheres still contained protein at day seven, pPB-HSA plasma and liver concentrations were decreased. This reduction was associated with an antibody response against the human albumin-based carrier protein, which was prevented by using a mouse albumin-based equivalent (pPB-MSA). In conclusion, this study shows that our polymeric microspheres are suitable as sustained release formulation for targeted protein constructs such as pPB-HSA. These formulations could be applied for the long-term treatment of chronic diseases such as liver fibrosis.
引用
收藏
页码:258 / 265
页数:8
相关论文
共 50 条
  • [41] Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation
    Teramura, T
    Watanabe, T
    Higuchi, S
    Hashimoto, K
    XENOBIOTICA, 1997, 27 (02) : 203 - 216
  • [42] Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen
    Wang, P
    Qi, M
    Zhong, D
    Fang, L
    BIOMEDICAL CHROMATOGRAPHY, 2003, 17 (01) : 58 - 61
  • [43] An ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects
    Richards, LS
    Behrle, JA
    Nichols, AI
    Fruncillo, RJ
    Paul, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P84 - P84
  • [44] Targeted truncated TGF-β receptor type II delivery to fibrotic liver by PDGF receptor-binding peptide modification for improving the anti-fibrotic activity against hepatic fibrosis in vitro and in vivo
    Huang, Zhen
    Ding, Minglu
    Dong, Yixin
    Ma, Manman
    Song, Xudong
    Liu, Yong
    Gao, Zhihan
    Guan, Huilin
    Chu, Yanhui
    Feng, Hua
    Wang, Xiaohua
    Liu, Haifeng
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 188 : 941 - 949
  • [45] COMPARATIVE PHARMACOKINETICS OF KETOPROFEN DERIVED FROM SINGLE ORAL DOSES OF KETOPROFEN CAPSULES OR A NOVEL SUSTAINED-RELEASE PELLET FORMULATION
    HOUGHTON, GW
    DENNIS, MJ
    RIGLER, ED
    PARSONS, RL
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1984, 5 (03) : 203 - 209
  • [46] Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
    Bader, Miaad
    Li, Yazhou
    Lecca, Daniela
    Rubovitch, Vardit
    Tweedie, David
    Glotfelty, Elliot
    Rachmany, Lital
    Kim, Hee Kyung
    Choi, Ho-Il
    Hoffer, Barry J.
    Pick, Chaim G.
    Greig, Nigel H.
    Kim, Dong Seok
    NEUROBIOLOGY OF DISEASE, 2019, 124 : 439 - 453
  • [47] Development, Physicochemical Characteristics and Pharmacokinetics of a New Sustained-Release Bilayer Tablet Formulation of Tramadol with an Immediate-Release Component for Twice-Daily Administration
    Ishitsubo, Naoki
    Oguro, Shinji
    Shimahashi, Hirotoshi
    Kawanishi, Masato
    Adachi, Takeshi
    Mitsuda, Kenji
    Ishibashi, Nobuyuki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2024, 49 (01) : 87 - 100
  • [48] Development, Physicochemical Characteristics and Pharmacokinetics of a New Sustained-Release Bilayer Tablet Formulation of Tramadol with an Immediate-Release Component for Twice-Daily Administration
    Naoki Ishitsubo
    Shinji Oguro
    Hirotoshi Shimahashi
    Masato Kawanishi
    Takeshi Adachi
    Kenji Mitsuda
    Nobuyuki Ishibashi
    European Journal of Drug Metabolism and Pharmacokinetics, 2024, 49 : 87 - 100
  • [49] PHARMACOKINETICS OF A SUSTAINED-RELEASE FORMULATION OF PYRIDOXAL-PHOSPHATE OF BUFLOMEDIL AFTER SINGLE OR REPEATED ORAL DOSES IN HEALTHY-VOLUNTEERS
    DIVALSERRA, MD
    GERMOGLI, R
    FELETTI, F
    COVINI, D
    BORGONOVO, E
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1992, 42-1 (05): : 632 - 636
  • [50] PHARMACOKINETICS OF CLONIDINE AND CHLORTHALIDONE FOLLOWING SUB-ACUTE ADMINISTRATION OF A FIXED COMBINATION COMPARED WITH A SUSTAINED-RELEASE FORMULATION OF CLONIDINE ALONE
    ARNDTS, D
    DOEVENDANS, J
    ARENDT, G
    RIPPEN, G
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1981, 31-2 (11): : 1954 - 1957